BridgeMD
New treatment option for Breast Neoplasms
Official title Transcutaneous Electrical Acupoint Stimulation on Symptoms Associated with Chemotherapy Induced Peripheral Neuropathy
ClinicalTrials.gov ID: NCT05904340
What this study is testing
- What it's testing
- Breast cancer ranks first in Taiwan's top ten gynecological cancers. Chemotherapy is a standard treatment method for colorectal cancer and breast cancer, but while destroying cancer cells, it also destroys healthy cells, resulting in side effects.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Primary diagnosed with breast cancer for the first time by a physician.
- Patients who have completed chemotherapy or postoperative adjuvant chemotherapy within 3 months, and the chemotherapy drugs used are paclitaxel...
- Patients who have been evaluated by doctors as peripheral neuropathy caused by chemotherapy, and whose symptoms persist after completing chemotherapy.
- Peripheral sensory or peripheral motor neuropathy grade ≥ 2 in general toxicity criteria (NCI-CTCAE).
- Those who have clear consciousness and can communicate in Mandarin or Taiwanese.
You likely can't join if
- Patients suffering from carcinoma in situ.
- Patients suffering from stage IV cancer.
- Patients suffering from metastatic cancer.
- Patients receiving peripheral neuropathy drugs (Duloxetine)
- Patients receiving acupoint stimulation therapy.
- Patients who are allergic to silicone patches.
See the full eligibility criteria
- Primary diagnosed with breast cancer for the first time by a physician.
- Patients who have completed chemotherapy or postoperative adjuvant chemotherapy within 3 months, and the chemotherapy drugs used are paclitaxel, vinblastine or platinum drugs.
- Patients who have been evaluated by doctors as peripheral neuropathy caused by chemotherapy, and whose symptoms persist after completing chemotherapy.
- Peripheral sensory or peripheral motor neuropathy grade ≥ 2 in general toxicity criteria (NCI-CTCAE).
- Those who have clear consciousness and can communicate in Mandarin or Taiwanese.
- Patients suffering from carcinoma in situ.
- Patients suffering from stage IV cancer.
- Patients suffering from metastatic cancer.
- Patients receiving peripheral neuropathy drugs (Duloxetine)
- Patients receiving acupoint stimulation therapy.
- Patients who are allergic to silicone patches.
- Patients with cardiac pacemakers.
- Patients suffering from diabetic peripheral neuropathy.
- Patients suffering from peripheral neuropathy of acquired immunodeficiency syndrome.
- Patients receiving treatment for mental illness.
The study team makes the final eligibility decision.
Where it's taking place
- Changhua, Changhua, Taiwan
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Changhua, Changhua, Taiwan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.